“Regenerative” is currently doing the work of six different nouns.
Growth factors, epidermal growth factor, fibroblast-conditioned media, exosomes, PDRN, polynucleotides, peptides, PRP, and post-procedure serums are routinely arranged under one glossy umbrella. The promise is that these products do something more intelligent than moisturize: signal, repair, remodel, communicate, or persuade tissue to behave younger.
Some of that language comes from legitimate biology. The category problem is that biologically active-sounding materials do not share one evidence file.
Growth factor is a function category, not one ingredient
Growth factors are signaling proteins involved in processes such as cell proliferation, migration, differentiation, angiogenesis, and wound repair. EGF is one growth factor. FGF, TGF-beta, PDGF, VEGF, and others have different targets and roles.
A product saying “growth factors” is therefore less specific than a product identifying which factors are present, their source, their stability, and whether the finished preparation was clinically tested.
EGF is not shorthand for every growth-factor serum
Epidermal growth factor has a specific receptor and biological pathway. Topical EGF-containing products are marketed for photoaging and post-procedure recovery, but a large protein applied to intact skin still has a delivery problem.
Formulation, protein stability, molecular size, skin condition, delivery technology, and whether the barrier has been deliberately disrupted can all change exposure. “Contains EGF” does not answer how much reaches a biologically relevant site.
The clinical literature is promising and still modest
A 2023 systematic review of topical growth-factor preparations for facial rejuvenation identified 33 studies and 1,180 participants, including nine randomized controlled trials. Investigator-assessed improvements were generally modest, and the literature was highly heterogeneous across sources, combinations, formulations, and endpoints. Several comparative randomized trials did not show statistically significant differences between treatments.
That is a more useful conclusion than either “growth factors are proven” or “they are useless.” There is evidence. It is not yet a standardized category with predictable product-to-product performance.
Conditioned media is not the same thing as purified EGF
Some products use media derived from cultured cells, fibroblast secretions, lysates, or proprietary mixtures containing multiple cytokines and growth factors. These preparations can contain a complex signaling mixture rather than one purified recombinant protein.
That complexity may be intentional. It also makes comparison harder. Two products described as “growth factor serum” may have entirely different biological contents.
Peptides are smaller signals with a different evidence problem
Cosmetic peptides can act as signal peptides, carrier peptides, enzyme-inhibiting peptides, neurotransmitter-inhibiting peptides, or other functional classes. They are not growth factors, although marketing sometimes uses “cell-signaling” language that makes the categories sound interchangeable.
Smaller molecular size may make some peptides easier to formulate for topical use, but peptide evidence remains sequence- and formula-specific. A peptide serum does not become a growth-factor product because both are described as “messengers.”
PDRN is a nucleotide material, not a growth factor
Polydeoxyribonucleotide consists of DNA-derived fragments and has a regenerative-medicine literature tied to wound repair and tissue signaling. Its proposed biology is different from applying a growth-factor protein.
PDRN is increasingly marketed topically, while much of its historical evidence comes from injectable or other medical contexts. Newer research is beginning to examine topical delivery more directly. The route remains part of the evidence.
Exosomes are not growth factors in a bottle
Exosomes are extracellular vesicles that can carry proteins, lipids, nucleic acids, and other signaling cargo. They are biologically interesting precisely because they are complex delivery packages, not single growth factors.
In the United States, FDA has stated that there are no FDA-approved exosome products. That regulatory fact should remain visible whenever a med spa sells an “exosome facial,” “exosome microneedling,” or post-laser exosome add-on.
A sophisticated biological concept does not become a legally standardized aesthetic product category because the treatment menu uses the word.
PRP contains growth factors, but the patient’s blood is part of the product
Platelet-rich plasma and platelet-rich fibrin are autologous blood-derived preparations. They can contain platelet-associated growth factors, but results depend on preparation method, platelet concentration, leukocyte content, activation, delivery, indication, and combination procedure.
PRP evidence cannot be used to validate a topical growth-factor serum merely because both involve signaling proteins.
Barrier disruption changes everything
A cosmetic applied to intact skin faces the stratum corneum. A product applied immediately after ablative laser or microneedling may encounter a temporarily altered barrier. That can improve delivery and simultaneously increase the importance of sterility, product composition, intended route, preservative systems, and safety.
The procedure does not confer approval on whatever vial is placed next to it.
“Stem cell” language usually needs translation too
Some skincare uses “stem cell conditioned media,” “stem cell proteins,” or plant stem-cell language. These phrases can describe very different materials. A cosmetic containing botanical stem-cell extract is not a stem-cell therapy. A human-cell-conditioned medium is not a live stem-cell treatment.
The source, processing, actual contents, and claims should be named plainly enough that the reader does not have to reverse-engineer the biology from branding.
Regulatory language puts a limit on the most ambitious claims
FDA determines whether a topical product is a cosmetic or a drug partly by intended use. Claims to regenerate cells, affect body structure or function, treat disease, or produce wound healing can move a product outside ordinary cosmetic territory.
This is especially relevant to regenerative skincare because the category’s favorite verbs—regenerate, repair tissue, stimulate growth, remodel—are not merely poetic when used as literal biological claims.
Where the evidence is strongest enough to be interesting
Topical growth-factor preparations have enough prospective clinical literature to justify serious discussion of photoaging and selected post-procedure applications. Some randomized studies report improvements in fine lines, texture, or recovery outcomes. The effect sizes are generally not procedure-like, and long-term comparative data remain limited.
The evidence becomes weaker when a brand cites generic wound-healing biology, studies on a different source material, or injectable data rather than the finished topical formula.
How to read a “regenerative” product page
- Name the material. EGF, a defined growth-factor blend, conditioned media, peptide complex, PDRN, exosomes, PRP, or something else?
- Name the source. Recombinant protein, fibroblast-conditioned medium, platelet preparation, salmon-derived nucleotides, plant extract?
- Name the route. Intact-skin cosmetic, post-procedure topical, injected product, autologous preparation?
- Name the evidence. Finished-product randomized trial, uncontrolled case series, raw-material study, cell culture, animal model?
- Name the endpoint. Hydration, fine lines, erythema recovery, histology, wound healing, collagen markers?
- Name the regulatory status. Cosmetic, approved drug/device, autologous procedure, unapproved biologic claim?
A high-tech bottle can still be a moisturizer with a research problem
Many growth-factor and regenerative formulas also contain glycerin, hyaluronic acid, silicones, emollients, peptides, niacinamide, antioxidants, and barrier-support ingredients. Those can make the skin look and feel better regardless of the headline biological.
That is not a flaw. It simply means the finished-product improvement may not prove that the prestige ingredient was responsible.
The Verdict
Vanity: Regenerative skincare contains some of the most interesting formulation and translational science in aesthetics. Topical growth factors have a real, if heterogeneous, clinical literature. PDRN has an evolving route-specific evidence base. Peptides can be rational actives. PRP is a legitimate procedural category in selected uses.
Vice: The umbrella term lets every technology borrow prestige from every other one. Exosomes borrow from stem-cell science. Serums borrow from wound healing. Peptides borrow from protein signaling. PDRN borrows from injectable regenerative medicine. The result can sound far more settled than the finished product evidence actually is.
Do not ask whether “regenerative skincare” works. Ask what the material is, how it reaches the target, what was tested, and what the product is legally and clinically allowed to claim.
Sources worth opening
- 2023 systematic review of topical growth-factor preparations for facial rejuvenation
- Randomized controlled trial of a topical growth-factor product for facial photodamage
- 2024 systematic review of anti-aging cosmeceutical evidence
- 2026 topical PDRN delivery and photodamage study
- FDA public safety notification on exosome products
- FDA cosmetic versus drug intended-use guidance
Method note: This is a category translator, not a recommendation for biologic or regenerative procedures. It follows the Vanity or Vice Editorial Standards.